1h Free Analyst Time
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018Speak directly to the analyst to clarify any post sales queries you may have.
Summary:
This latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.
Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.
Report Highlights:
This latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 1 and 2 respectively.
Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)
Reasons for Purchase:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport Coverage
Vaginal Atrophy (Atrophic Vaginitis) - Overview
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
Ligand Pharmaceuticals Inc
Medinova AG
Mithra Pharmaceuticals SA
TherapeuticsMD Inc
Vaginal Atrophy (Atrophic Vaginitis) - Drug Profiles
(estriol + lactobacillus) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lasofoxifene tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TX-006HR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TX-008HR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
Featured News & Press Releases
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals Inc, H1 2018
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Medinova AG, H1 2018
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA, H1 2018
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc, H1 2018
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ligand Pharmaceuticals Inc
- Medinova AG
- Mithra Pharmaceuticals SA
- TherapeuticsMD Inc
